Richard Harris

Doby Photography
/ NPR

Award-winning journalist Richard Harris has reported on a wide range of topics in science, medicine and the environment since he joined NPR in 1986. In early 2014, his focus shifted from an emphasis on climate change and the environment to biomedical research.

Harris has traveled to all seven continents for NPR. His reports have originated from Timbuktu, the South Pole, the Galapagos Islands, Beijing during the SARS epidemic, the center of Greenland, the Amazon rain forest, the foot of Mt. Kilimanjaro (for a story about tuberculosis), and Japan to cover the nuclear aftermath of the 2011 tsunami.In 2010, Harris' reporting revealed that the blown-out BP oil well in the Gulf of Mexico was spewing out far more oil than asserted in the official estimates. That revelation led the federal government to make a more realistic assessment of the extent of the spill.

Harris covered climate change for decades. He reported from the United Nations climate negotiations, starting with the Earth Summit in Rio de Janeiro in 1992, and including Kyoto in 1997 and Copenhagen in 2009. Harris was a major contributor to NPR's award-winning 2007-2008 "Climate Connections" series.

Over the course of his career, Harris has been the recipient of many prestigious awards. Those include the American Geophysical Union's 2013 Presidential Citation for Science and Society. He shared the 2009 National Academy of Sciences Communication Award and was a finalist again in 2011. In 2002, Harris was elected an honorary member of Sigma Xi, the scientific research society. Harris shared a 1995 Peabody Award for investigative reporting on NPR about the tobacco industry. Since 1988, the American Association for the Advancement of Science has honored Harris three times with its science journalism award.

Before joining NPR, Harris was a science writer for the San Francisco Examiner. From 1981 to 1983, Harris was a staff writer at The Tri-Valley Herald in Livermore, California, covering science, technology, and health issues related to the nuclear weapons lab in Livermore. He started his career as an AAAS Mass Media Science Fellow at the now-defunct Washington (DC) Star.

Harris is co-founder of the Washington, D.C., Area Science Writers Association, and is past president of the National Association of Science Writers. He serves on the board of the Council for the Advancement of Science Writing.

A California native, Harris returned to the University of California-Santa Cruz in 2012, to give a commencement address at Crown College, where he had given a valedictory address at his own graduation. He earned a bachelor's degree at the school in biology, with highest honors.

If you think your hearing is just fine, think again. A federal study finds that about a quarter of people between the ages of 20 and 69 who think their hearing is good or excellent are in fact showing signs of hearing loss.

Hearing loss is often chalked up to noisy work environments or to aging. To be sure, those are major reasons that people's hearing becomes less acute. The Centers for Disease Control and Prevention's latest survey on hearing finds that 24 percent of hearing loss is due to loud workplaces.

A widely used blood test to measure blood-sugar trends can give imprecise results, depending on a person's race and other factors. This test means diabetes can sometimes be misdiagnosed or managed poorly.

Doctors have been cautioned before that results from the A1C test don't have pinpoint accuracy. A study published Tuesday underscores that shortcoming as it applies to people who carry the sickle cell trait.

When scientists first read out the human genome 15 years ago, there were high hopes that we'd soon understand how traits like height are inherited. It hasn't been easy. A huge effort to find height-related genes so far only explains a fraction of this trait.

Now scientists say they've made some more headway. And the effort is not just useful for understanding how genes determine height, but how they're involved in driving many other human traits.

The first results from a major project to measure the reliability of cancer research have highlighted a big problem: Labs trying to repeat published experiments often can't.

That's not to say that the original studies are wrong. But the results of a review published Thursday, in the open-access journal eLife, are a sobering reminder that science often fails at one of its most basic requirements — an experiment in one lab ought to be reproducible in another one.

A Canadian doctor who is opposed to a widely used drug for morning sickness has fired another volley.

Writing in the journal PLOS ONE, Dr. Navindra Persaud in the department of family and community medicine at St. Michael's Hospital in Toronto, notes that an unpublished study that supported use of the drug, conducted in the 1970s, is seriously flawed.

The federal government will pay more than $100,000 to give someone a kidney transplant, but after three years, the government will often stop paying for the drugs needed to keep that transplanted kidney alive.

Constance Creasey is one of the thousands of people who find themselves caught up by this peculiar feature of the federal kidney program.

There's a bump in the number of cases of the mumps this year in the United States.

This highly infectious disease is much less hazardous than it was decades ago, but health officials are still reacting strongly to several big outbreaks.

Most years, health officials report a few hundred cases of mumps, but this year the total has topped 4,000. Most are clustered in Iowa, Illinois and, worst of all, Arkansas, which has more than 2,200 cases.

Two widely used tests to analyze the genetics of tumors often don't come to the same conclusions, according to head-to-head analyses.

Authors of two recent studies comparing these tests say doctors need to be careful not to assume that these tests are providing a complete picture of a tumor's genetic variants, when using them to select treatments for cancer patients.

Updated Dec. 1, 9:05 a.m.: The House of Representatives voted overwhelmingly on Wednesday to approve the 21st Century Cures Act, a sprawling bill to fund medical research and revamp how drugs and medical devices are approved by the Food and Drug Administration.

Patients and their advocates are getting an ever-larger voice in how medical research is carried out. They participate in the design of experiments and have a greater say in what outcomes they care about most — and it's not always simply living longer.

Sharon Terry has lived through a couple of decades during which patients went from being complete outsiders to participants. She worries now that they risk being co-opted by the medical research juggernaut.